CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $2.68M
- P/E (TTM)
- –
- Dividend yield
- –
About Creative Medical Technology
Biological Products, (No Diagnostic Substances), SIC 2836
Creative Medical Technologies Holdings, Inc. is a commercial-stage biotechnology company focused on advancing regenerative therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. The company develops cell-based technologies and therapeutic platforms, notably ImmCelz, an autologous reprogrammed immune cell therapy, and AlloStem, an allogeneic human perinatal tissue-derived cell program. Its clinical and development pipeline targets multiple indications, including chronic lower back pain caused by degenerative disc disease, type 1 diabetes, female infertility, and erectile dysfunction. In addition, the enterprise pursues biodefense and therapeutic modeling initiatives that combine induced pluripotent stem cells with artificial intelligence. Its operations serve clinical trial populations and patients suffering from chronic, debilitating, or autoimmune conditions.
The company conducts its clinical and research activities in the United States, operating through corporate subsidiaries such as Creative Medical Technologies, ImmCelz, and StemSpine. Its principal executive offices are located in Phoenix, Arizona.
Summary of the business section of Creative Medical Technology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
- Founded
- 1998
- Headquarters
- Phoenix, AZ
- Address
- 211 E. Osborn Rd. 85012
- Phone
- (480) 399-2822
- Website
- clinicaltrials.gov
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Haynie, Salt Lake City, Utah
Stock & identifiers
- Ticker
- CELZ
- Exchange
- Nasdaq
- IPO date
- Nov 6, 2015
- Shares outstanding
- 7M, Aug 7, 2026
- Public float
- $4.63M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jun 12, 2023; 1-for-500 reverse, Nov 10, 2021; 1-for-150 reverse, Apr 6, 2020; 1-for-150 reverse, Feb 3, 2020
- SEC CIK
- 1187953
- CUSIP
- 22529Y408
- ISIN
- US22529Y4089
- EIN
- 87-0622284
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Timothy Warbington | President & CEO, Director | 1,047,113 |
| Acquisition Corp. Creative | Director | – |
| Michael H. Finger | Director | 351 |
Corporate history
Events identified from SEC filings